Catalyst Biosciences (NASDAQ:CBIO) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.01, Fidelity Earnings reports.
Shares of CBIO stock traded up $0.14 on Friday, reaching $5.70. The company’s stock had a trading volume of 72,700 shares, compared to its average volume of 183,292. The company has a quick ratio of 15.83, a current ratio of 15.83 and a debt-to-equity ratio of 0.02. Catalyst Biosciences has a 12-month low of $4.52 and a 12-month high of $11.29. The company has a market capitalization of $70.05 million, a P/E ratio of -2.13 and a beta of 2.18. The stock’s 50 day simple moving average is $5.52 and its 200-day simple moving average is $7.15.
CBIO has been the subject of a number of analyst reports. ValuEngine raised Catalyst Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Chardan Capital set a $25.00 price objective on Catalyst Biosciences and gave the stock a “buy” rating in a research report on Sunday, August 25th. Finally, Zacks Investment Research downgraded Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Catalyst Biosciences has a consensus rating of “Buy” and a consensus price target of $20.38.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Further Reading: How Do Investors Open a Backdoor Roth IRA?
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.